Cargando…
One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes
OBJECTIVE: To evaluate the effect of a 1-year hybrid closed-loop (HCL) system on glycemic control in children and adolescents with type 1 diabetes (T1D) previously treated with multiple daily injections (MDI). METHODS: This was a 1-year observational study, as a continuation of the previous 3 months...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548407/ https://www.ncbi.nlm.nih.gov/pubmed/33044604 http://dx.doi.org/10.1007/s00592-020-01607-4 |
_version_ | 1783592608280346624 |
---|---|
author | Petrovski, Goran Al Khalaf, Fawziya Campbell, Judith Umer, Fareeda Almajaly, Douha Hamdan, Manar Hussain, Khalid |
author_facet | Petrovski, Goran Al Khalaf, Fawziya Campbell, Judith Umer, Fareeda Almajaly, Douha Hamdan, Manar Hussain, Khalid |
author_sort | Petrovski, Goran |
collection | PubMed |
description | OBJECTIVE: To evaluate the effect of a 1-year hybrid closed-loop (HCL) system on glycemic control in children and adolescents with type 1 diabetes (T1D) previously treated with multiple daily injections (MDI). METHODS: This was a 1-year observational study, as a continuation of the previous 3 months prospective study of pediatric patients with T1D conducted at Sidra Medicine in Qatar. The study enrolled individuals aged 7–18 years with T1D > 1 year, on MDI with self-monitoring of blood glucose or continuous glucose monitoring, with no prior pump experience, and with an HbA1c level < 12.5% (< 113 mmol/mol). After the first 3 months of HCL use, patients were followed at 6, 9 and 12 months, where HbA1c was obtained and pump data were collected. RESULTS: All 30 participants (age 10.24 ± 2.6 years) who initiated HCL completed 12 months of HCL system use in Auto Mode. The participants used the sensor 88.4 ± 6.5% of the time with Auto Mode usage 85.6 ± 7.4% during 12 months of HCL system use. HbA1c decreased from 8.2 ± 1.4% (66 ± 15.3 mmol/mol) at baseline, to 6.7 ± 0.5% (50 ± 5.5 mmol/mol) at 3 months (p = 0.02) and remained stable to 7.1 ± 0.6 (54 ± 6.6 mmol/mol) at 12 months (p = 0.02). TIR (70–180 mg/dL) increased from 46.9% at baseline to 71.9% at 1 month and remained above 70% during the 12 months of HCL use. CONCLUSION: HCL system (MiniMed 670G) in children and adolescents previously treated with MDI significantly improves glycemic outcomes (HbA1c and Time in Ranges) immediately during the first month. This improved glycemic control was maintained over the 1 year following Auto Mode initiation. |
format | Online Article Text |
id | pubmed-7548407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-75484072020-10-14 One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes Petrovski, Goran Al Khalaf, Fawziya Campbell, Judith Umer, Fareeda Almajaly, Douha Hamdan, Manar Hussain, Khalid Acta Diabetol Original Article OBJECTIVE: To evaluate the effect of a 1-year hybrid closed-loop (HCL) system on glycemic control in children and adolescents with type 1 diabetes (T1D) previously treated with multiple daily injections (MDI). METHODS: This was a 1-year observational study, as a continuation of the previous 3 months prospective study of pediatric patients with T1D conducted at Sidra Medicine in Qatar. The study enrolled individuals aged 7–18 years with T1D > 1 year, on MDI with self-monitoring of blood glucose or continuous glucose monitoring, with no prior pump experience, and with an HbA1c level < 12.5% (< 113 mmol/mol). After the first 3 months of HCL use, patients were followed at 6, 9 and 12 months, where HbA1c was obtained and pump data were collected. RESULTS: All 30 participants (age 10.24 ± 2.6 years) who initiated HCL completed 12 months of HCL system use in Auto Mode. The participants used the sensor 88.4 ± 6.5% of the time with Auto Mode usage 85.6 ± 7.4% during 12 months of HCL system use. HbA1c decreased from 8.2 ± 1.4% (66 ± 15.3 mmol/mol) at baseline, to 6.7 ± 0.5% (50 ± 5.5 mmol/mol) at 3 months (p = 0.02) and remained stable to 7.1 ± 0.6 (54 ± 6.6 mmol/mol) at 12 months (p = 0.02). TIR (70–180 mg/dL) increased from 46.9% at baseline to 71.9% at 1 month and remained above 70% during the 12 months of HCL use. CONCLUSION: HCL system (MiniMed 670G) in children and adolescents previously treated with MDI significantly improves glycemic outcomes (HbA1c and Time in Ranges) immediately during the first month. This improved glycemic control was maintained over the 1 year following Auto Mode initiation. Springer Milan 2020-10-12 2021 /pmc/articles/PMC7548407/ /pubmed/33044604 http://dx.doi.org/10.1007/s00592-020-01607-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Petrovski, Goran Al Khalaf, Fawziya Campbell, Judith Umer, Fareeda Almajaly, Douha Hamdan, Manar Hussain, Khalid One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
title | One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
title_full | One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
title_fullStr | One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
title_full_unstemmed | One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
title_short | One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
title_sort | one-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548407/ https://www.ncbi.nlm.nih.gov/pubmed/33044604 http://dx.doi.org/10.1007/s00592-020-01607-4 |
work_keys_str_mv | AT petrovskigoran oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes AT alkhalaffawziya oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes AT campbelljudith oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes AT umerfareeda oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes AT almajalydouha oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes AT hamdanmanar oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes AT hussainkhalid oneyearexperienceofhybridclosedloopsysteminchildrenandadolescentswithtype1diabetespreviouslytreatedwithmultipledailyinjectionsdriverstosuccessfuloutcomes |